Phase 2 Polyneuropathy Clinical Trials
8 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–8 of 8 trials
Recruiting
Phase 2
Zanubritnib and Anti-MAG Neuropathy
Anti-MAG IgM-associated Demyelinating Polyneuropathy
Azienda Ospedaliera di Padova50 enrolled1 locationNCT07392229
Recruiting
Phase 2
IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Chronic Inflammatory Demyelinating Polyneuropathy
Immunovant Sciences GmbH162 enrolled135 locationsNCT07032662
Recruiting
Phase 2
Peripheral Magnetic Stimulation With Balance Training to Decrease Fall Risks in Diabetic Polyneuropathy
Diabetic Polyneuropathy
Queen Savang Vadhana Memorial Hospital, Thailand40 enrolled1 locationNCT07000214
Recruiting
Phase 2
IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies
Small Fiber NeuropathyAutoimmune Small Fiber NeuropathyInflammatory Polyneuropathy+1 more
Endeavor Health20 enrolled1 locationNCT04153422
Recruiting
Phase 2
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
Chronic Inflammatory Demyelinating Polyneuropathy
Nuvig Therapeutics, Inc.60 enrolled1 locationNCT07027111
Not Yet Recruiting
Phase 2
A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Chronic Inflammatory Demyelinating Polyneuropathy
Nuvig Therapeutics60 enrolled9 locationsACTRN12625000534482
Recruiting
Phase 2
The Effect of Alpha Lipoid Acid and Vitamin B Preparation on Diabetic Polyneuropathy in Type 2 Diabetes Mellitus Patient
Diabetic Polyneuropathy
Universiti Sains Malaysia76 enrolled1 locationNCT06568185
Recruiting
Phase 1Phase 2
A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Transthyretin Amyloidosis PolyneuropathyTransthyrexin Amyloidosis Cardiomyopathy
YolTech Therapeutics Co., Ltd31 enrolled3 locationsNCT06539208